BioAtla Stock (NASDAQ:BCAB)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$2.09

52W Range

$1.14 - $4.02

50D Avg

$1.87

200D Avg

$2.14

Market Cap

$96.67M

Avg Vol (3M)

$1.16M

Beta

1.04

Div Yield

-

BCAB Company Profile


BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

65

IPO Date

Dec 16, 2020

Website

BCAB Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceJun 21
Service$300.00K

Fiscal year ends in Dec 23 | Currency in USD

BCAB Financial Summary


Dec 23Dec 22Dec 21
Revenue--$250.00K
Operating Income$-129.69M$-108.14M$-96.44M
Net Income-$-105.28M$-95.41M
EBITDA$-129.69M$-106.48M$-94.76M
Basic EPS-$-2.70$-2.76
Diluted EPS-$-2.70$-2.76

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 11, 24 | 1:32 AM
Q1 24May 14, 24 | 8:35 PM
Q4 23Mar 26, 24 | 7:21 PM

Peer Comparison


TickerCompany
GRCLGracell Biotechnologies Inc.
OLMAOlema Pharmaceuticals, Inc.
NRIXNurix Therapeutics, Inc.
PMVPPMV Pharmaceuticals, Inc.
KYMRKymera Therapeutics, Inc.
IKNAIkena Oncology, Inc.
FHTXFoghorn Therapeutics Inc.
IPSCCentury Therapeutics, Inc.
AVTEAerovate Therapeutics, Inc.
ERASErasca, Inc.
ACRVAcrivon Therapeutics, Inc. Common Stock
PASGPassage Bio, Inc.
ANTXAN2 Therapeutics, Inc.
CCCCC4 Therapeutics, Inc.
GLUEMonte Rosa Therapeutics, Inc.
DSGNDesign Therapeutics, Inc.
RZLTRezolute, Inc.
ADAGAdagene Inc.
NAUTNautilus Biotechnology, Inc.
STTKShattuck Labs, Inc.